133 related articles for article (PubMed ID: 34785319)
1. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
[TBL] [Abstract][Full Text] [Related]
2. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif.
Ye S; MacEachran DP; Hamilton JW; O'Toole GA; Stanton BA
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C807-18. PubMed ID: 18650266
[TBL] [Abstract][Full Text] [Related]
3. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
4. Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death.
Kopecka J; Godel M; Dei S; Giampietro R; Belisario DC; Akman M; Contino M; Teodori E; Riganti C
Cells; 2020 Apr; 9(4):. PubMed ID: 32331368
[TBL] [Abstract][Full Text] [Related]
5. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
8. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.
Patel KJ; Tannock IF
BMC Cancer; 2009 Oct; 9():356. PubMed ID: 19807929
[TBL] [Abstract][Full Text] [Related]
9. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.
Tormo E; Ballester S; Adam-Artigues A; Burgués O; Alonso E; Bermejo B; Menéndez S; Zazo S; Madoz-Gúrpide J; Rovira A; Albanell J; Rojo F; Lluch A; Eroles P
Sci Rep; 2019 Mar; 9(1):5316. PubMed ID: 30926829
[TBL] [Abstract][Full Text] [Related]
10. Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.
Gazzano E; Rolando B; Chegaev K; Salaroglio IC; Kopecka J; Pedrini I; Saponara S; Sorge M; Buondonno I; Stella B; Marengo A; Valoti M; Brancaccio M; Fruttero R; Gasco A; Arpicco S; Riganti C
J Control Release; 2018 Jan; 270():37-52. PubMed ID: 29191785
[TBL] [Abstract][Full Text] [Related]
11. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
Jansson PJ; Yamagishi T; Arvind A; Seebacher N; Gutierrez E; Stacy A; Maleki S; Sharp D; Sahni S; Richardson DR
J Biol Chem; 2015 Apr; 290(15):9588-603. PubMed ID: 25720491
[TBL] [Abstract][Full Text] [Related]
12. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
13. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.
Doublier S; Belisario DC; Polimeni M; Annaratone L; Riganti C; Allia E; Ghigo D; Bosia A; Sapino A
BMC Cancer; 2012 Jan; 12():4. PubMed ID: 22217342
[TBL] [Abstract][Full Text] [Related]
14. Intracellular Doppler Spectroscopy detects altered drug response in SKOV3 tumor spheroids with silenced or inhibited P-glycoprotein.
Narayanan G; Merrill D; An R; Nolte DD; Turek JJ
Biochem Biophys Res Commun; 2019 Jul; 514(4):1154-1159. PubMed ID: 31103263
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
16. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
17. Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines.
Harstrick A; Vanhoefer U; Schleucher N; Schroeder J; Baumgart J; Scheulen ME; Wilke H; Seeber S
Anticancer Drugs; 1995 Oct; 6(5):681-5. PubMed ID: 8845478
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.
Kopecka J; Rankin GM; Salaroglio IC; Poulsen SA; Riganti C
Oncotarget; 2016 Dec; 7(52):85861-85875. PubMed ID: 27811376
[TBL] [Abstract][Full Text] [Related]
19. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
Riganti C; Voena C; Kopecka J; Corsetto PA; Montorfano G; Enrico E; Costamagna C; Rizzo AM; Ghigo D; Bosia A
Mol Pharm; 2011 Jun; 8(3):683-700. PubMed ID: 21491921
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
